BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 25029118)

  • 21. Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis.
    Boland JM; Maleszewski JJ; Wampfler JA; Voss JS; Kipp BR; Yang P; Yi ES
    Hum Pathol; 2018 Jan; 71():8-19. PubMed ID: 28823574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.
    Sousa V; Rodrigues C; Silva M; Alarcão AM; Carvalho L
    Rev Port Pneumol (2006); 2015; 21(3):113-25. PubMed ID: 25926253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma].
    Ma XL; Jia RN; Han K; Zhang YX
    Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):578-584. PubMed ID: 38825903
    [No Abstract]   [Full Text] [Related]  

  • 24. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation.
    Ichinokawa H; Ishii G; Nagai K; Kawase A; Yoshida J; Nishimura M; Hishida T; Ogasawara N; Tsuchihara K; Ochiai A
    Hum Pathol; 2013 Dec; 44(12):2636-42. PubMed ID: 24119562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
    Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
    J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
    Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
    Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
    Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
    J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients.
    Wang T; Zhang Y; Liu B; Hu M; Zhou N; Zhi X
    Thorac Cancer; 2017 Nov; 8(6):600-605. PubMed ID: 28940943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.
    Dong YJ; Cai YR; Zhou LJ; Su D; Mu J; Chen XJ; Zhang LI
    Oncol Lett; 2016 Apr; 11(4):2552-2558. PubMed ID: 27073516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations.
    Jie-Liu ; Li XY; Zhao YQ; Liu RQ; Zhang JB; Ma J; Chen LJ; Hu XF
    Pathol Res Pract; 2014 Mar; 210(3):176-81. PubMed ID: 24370340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.
    Pareja F; Crapanzano JP; Mansukhani MM; Bulman WA; Saqi A
    Cancer Cytopathol; 2015 Mar; 123(3):162-70. PubMed ID: 25557162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines.
    Ferretti GR; Busser B; de Fraipont F; Reymond E; McLeer-Florin A; Mescam-Mancini L; Moro-Sibilot D; Brambilla E; Lantuejoul S
    Lung Cancer; 2013 Oct; 82(1):69-75. PubMed ID: 23927885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma.
    Wang H; Zhang W; Wang K; Li X
    Medicine (Baltimore); 2018 Jun; 97(26):e11116. PubMed ID: 29952952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of IASLC/ATS/ERS Histologic Subtypes of Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations in 320 Resected Cases.
    Nakamura H; Saji H; Shinmyo T; Tagaya R; Kurimoto N; Koizumi H; Takagi M
    Clin Lung Cancer; 2015 May; 16(3):209-15. PubMed ID: 25467929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung.
    Zenali MJ; Weissferdt A; Solis LM; Ali S; Tang X; Mehran RJ; Wistuba II; Moran CA; Kalhor N
    Hum Pathol; 2015 Jun; 46(6):836-42. PubMed ID: 25776025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
    Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
    J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.